Want to see SPRO full AI Analyst Report?
Top Page
Spero Therapeutics
(NASDAQ:SPRO)
Select Model
Select Model
Rating:64Neutral
Price Target:
$1.50
▲(23.97% Upside)
Action:Reiterated
Date:09/23/26
The score is primarily supported by improved TTM profitability/cash generation and a low-debt balance sheet, plus an earnings-call-driven de-risking of funding and strategy via the $105M non-dilutive financing and Utebzi approval. Offsetting these positives are weak technicals (below long-term moving averages with negative MACD) and fundamental volatility, including declining TTM revenue and the recent quarter’s $0 revenue with a wider net loss.
Positive Factors
Utebzi FDA Approval and GSK Commercialization
Utebzi’s approval converts a major development program into an approved product with an established commercial partner. GSK’s planned U.S. launch can create milestone and royalty opportunities for Spero while allowing the company to benefit from commercialization without building a large sales infrastructure.
Negative Factors
Unreliable Collaboration-Driven Revenue
The sharp revenue swing highlights that Spero does not yet have a stable, recurring product-sales base and remains exposed to the timing of collaboration payments. This makes operating performance and cash generation less predictable while Utebzi royalties and future milestones develop.
Read all positive and negative factors
Positive Factors
Negative Factors
Utebzi FDA Approval and GSK Commercialization
Utebzi’s approval converts a major development program into an approved product with an established commercial partner. GSK’s planned U.S. launch can create milestone and royalty opportunities for Spero while allowing the company to benefit from commercialization without building a large sales infrastructure.
Read all positive factors
Spero Therapeutics (SPRO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$69.30M
Dividend Yield0.52%
Average Volume (3M)680.66K
Price to Earnings (P/E)8.5
Beta (1Y)1.80
Revenue Growth26.04%
EPS GrowthN/A
CountryUS
Employees25
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.14
Shares Outstanding58,234,825
10 Day Avg. Volume1,373,896
30 Day Avg. Volume680,656
Financial Highlights & Ratios
PEG Ratio-0.14
Price to Book (P/B)2.21
Price to Sales (P/S)2.19
P/FCF Ratio-10.34
Enterprise Value/Market Cap1.15
Enterprise Value/Revenue1.85
Enterprise Value/Gross Profit1.85
Enterprise Value/Ebitda10.31
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.44
Revenue Forecast (FY)$800.00K
Spero Therapeutics Business Overview & Revenue Model
Company Description
Spero Therapeutics, Inc. is a biopharmaceutical firm in the clinical development stage, primarily focused on discovering, advancing, and commercializing innovative treatments for multi-drug resistant (MDR) bacterial infections and rare diseases wi...
How the Company Makes Money
Spero Therapeutics’ revenue model has primarily been partnership- and financing-driven rather than product-sales-driven. As a clinical-stage company, it has generally not depended on recurring revenue from marketed drugs; instead, when revenue has...
Spero Therapeutics Earnings Call Summary
Earnings Call Date:Aug 12, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 16, 2026
Earnings Call Sentiment Positive
The call conveyed a strategic positive shift: an important product approval (Utebzi), a high-value in-license (SP001) with a clear development plan in IgG4-RD, a non-dilutive $105M financing that extends runway into H2 2029, and a strengthened clinical leadership team. Offsetting these positives are an absence of current revenue (Q2 2026 revenue $0 vs $14.2M prior year), a wider net loss and increased loss per share, dependence on GSK royalty/milestone streams to service the financing, and SP001 remaining early-stage with a small planned Phase II. On balance, management’s actions materially de-risk near-term funding and position the company for an immunology strategy, but meaningful clinical and commercial execution risks remain.Positive Updates
FDA Approval of Utebzi (tebipenem pivoxil)
On June 17, 2026 the FDA approved Utebzi, the first and only oral carbapenem for complicated urinary tract infections (including pyelonephritis). Approval based on PIVOT-PO Phase III (stopped early for efficacy May 2025). GSK holds exclusive commercialization rights (excludes certain Asian territories where Meiji retains rights) and expects U.S. availability in the second half of 2026.
Negative Updates
No Revenue in Q2 2026 Versus Prior-Year Collaboration Revenue
Total revenue was $0 in Q2 2026 compared with $14.2 million in Q2 2025 (a decline of $14.2M or 100%), primarily because prior-period collaboration revenue from Pfizer and GSK and government awards were fully realized in prior periods.
Read all updates
Q2-2026 Updates
Positive
Negative
FDA Approval of Utebzi (tebipenem pivoxil)
On June 17, 2026 the FDA approved Utebzi, the first and only oral carbapenem for complicated urinary tract infections (including pyelonephritis). Approval based on PIVOT-PO Phase III (stopped early for efficacy May 2025). GSK holds exclusive commercialization rights (excludes certain Asian territories where Meiji retains rights) and expects U.S. availability in the second half of 2026.
Read all positive updates
Company Guidance
Spero said the key near‑term financial and development guidance is anchored by a $105.0M nondilutive, nonrecourse royalty financing (special‑purpose subsidiary issued $105M senior secured notes, 10% annual interest, 9‑year maturity, principal & interest payable quarterly from GSK Utebzi milestones/royalties; after repayment Spero retains 35% of additional GSK proceeds) and an exclusive SP001 license with Innovent with an estimated $1.1B total contingent value; cash & cash equivalents were $50.8M as of June 30 (pre‑financing) and, together with the financing, are expected to fund the $35M nonrefundable Innovent upfront plus operating and capex into the second half of 2029 (cash runway updated to 2H‑2029). Operational milestones include a Phase II IgG4‑RD trial planned to begin in Q2‑2027 (open‑label, 6 monthly doses, two dosing arms, up to ~15 patients per arm, i.e., ~30 patients total) and Utebzi availability in the U.S. in 2H‑2026; reported Q2‑2026 P&L metrics were net loss $9.6M (diluted loss per share $0.16) vs $1.7M ($0.03) in Q2‑2025, revenue $0 (vs $14.2M), R&D $3.4M (vs $10.7M) and G&A $6.5M (vs $5.9M).Spero Therapeutics Financial Statement Overview
Summary
Income Statement
66
Positive
Balance Sheet
78
Positive
Cash Flow
62
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 42.96M | 59.62M | 47.98M | 103.78M | 48.58M | 3.07M |
| Gross Profit | 42.96M | 59.62M | -48.78M | 52.34M | 48.58M | 3.07M |
| EBITDA | 7.70M | 8.83M | -72.48M | 27.15M | -42.94M | -87.17M |
| Net Income | 7.38M | 8.57M | -68.57M | 22.81M | -46.41M | -89.76M |
Balance Sheet | ||||||
| Total Assets | 52.77M | 68.92M | 110.54M | 182.39M | 124.80M | 171.07M |
| Cash, Cash Equivalents and Short-Term Investments | 50.77M | 40.27M | 52.89M | 76.33M | 109.11M | 146.40M |
| Total Debt | 2.04M | 2.90M | 4.30M | 5.54M | 6.65M | 7.33M |
| Total Liabilities | 8.56M | 9.90M | 64.42M | 75.50M | 48.87M | 82.78M |
| Stockholders Equity | 44.20M | 59.02M | 46.12M | 106.89M | 75.93M | 88.29M |
Cash Flow | ||||||
| Free Cash Flow | 19.58M | -12.62M | -23.44M | -32.99M | -7.73M | -64.35M |
| Operating Cash Flow | 19.58M | -12.62M | -23.44M | -32.99M | -7.73M | -64.35M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 33.81M | 7.67M |
| Financing Cash Flow | 0.00 | 0.00 | 0.00 | 221.00K | -29.55M | 84.05M |
Spero Therapeutics Technical Analysis
Negative
1.21
Price Trends
1.20
Negative
1.78
Negative
2.11
Negative
Market Momentum
>-0.01
Negative
46.81
Neutral
26.80
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SPRO, the sentiment is Negative. The current price of 1.21 is above the 20-day moving average (MA) of 1.19, above the 50-day MA of 1.20, and below the 200-day MA of 2.11, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 46.81 is Neutral, neither overbought nor oversold. The STOCH value of 26.80 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SPRO.
Spero Therapeutics Risk Analysis
Spero Therapeutics disclosed 65 risk factors in its most recent earnings report. Spero Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Spero Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | $69.30M | 8.50 | 16.17% | 0.52% | 26.04% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $41.89M | -1.17 | -708.20% | ― | ― | 30.16% | |
47 Neutral | $22.06M | -1.49 | -207.47% | ― | ― | 38.55% | |
46 Neutral | $32.67M | -3.11 | >-0.01% | ― | ― | 35.47% | |
44 Neutral | $119.94M | -1.00 | -1005.80% | 0.36% | -100.00% | 54.89% | |
42 Neutral | $29.23M | -1.21 | -60.32% | ― | ― | 71.26% |
* Healthcare Sector Average
SPRO
Spero Therapeutics
1.19
-0.90
-43.06%
INO
Inovio Pharmaceuticals
1.16
-1.25
-51.87%
NNVC
NanoViricides
1.28
-0.17
-11.72%
MCRB
Seres Therapeutics
2.94
-18.06
-86.00%
PDSB
PDS Biotechnology
0.75
-0.21
-22.25%
COCP
Cocrystal Pharma
1.15
-0.07
-6.15%
Spero Therapeutics Corporate Events
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Spero Therapeutics Launches New Jefferies ATM Equity Program
Neutral
Aug 28, 2026
On August 28, 2026, Spero Therapeutics, Inc. entered into a new Open Market Sale Agreement with Jefferies LLC, allowing the company, once its pending universal shelf registration statement becomes effective, to sell up to $100 million of common st...
Business Operations and StrategyPrivate Placements and Financing
Spero Therapeutics inks major CD40L and royalty deals
Positive
Jul 15, 2026
On July 8, 2026, Spero Therapeutics signed a global license and cross-license deal with Innovent Biologics for SP001, granting Spero exclusive rights to develop and commercialize the third-generation anti-CD40L antibody outside Greater China while...
Business Operations and StrategyShareholder Meetings
Spero Therapeutics Expands Stock Incentive Plan and Authorization
Positive
Jun 25, 2026
At its June 23, 2026 annual meeting, Spero Therapeutics stockholders approved a 2026 Stock Incentive Plan authorizing the issuance of up to 12,895,866 shares of common stock for equity-based compensation. At the same meeting, shareholders also app...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.